医学
贝伐单抗
恶性胸腔积液
腹水
顺铂
胸腔积液
不利影响
渗出
外科
化疗
存活率
内科学
胃肠病学
作者
Lixin Jiang,Peng Li,Zhaohui Gong,Bo Hu,Jing Ma,Jiahui Wang,Hongjin Chu,Liangming Zhang,Ping Sun,Jian Chen
出处
期刊:PubMed
日期:2016-03-01
卷期号:36 (3): 1313-8
被引量:21
摘要
To record the efficacy and toxicity of combining bevacizumab with cisplatin in treating malignant pleural effusion and ascites through intrapleural and intraperitoneal infusion.Forty-three patients were admitted to the Oncology Department of Yantai Yuhuangding Hospital with confirmed malignant effusion since January, 2011. Twenty of them received intrapleural and intraperitoneal perfusion of 200 mg bevacizumab plus 60 mg cisplatin every three weeks, and 23 patients received 60 mg cisplatin alone after draining effusion as much as possible. Reduction of effusion was determined by type-B ultrasonography.The complete remission rate and effective rate of bevacizumab group was superior to that of the cisplatin group. The quality of life recovery rate of bevacizumab group was superior to that of the cisplatin group. The anhelation and abdominal distention of bevacizumab group was significantly improved. There was no significant difference in level III/IV toxicities and adverse effects between two groups.Bevacizumab significantly improved the objective response rate and quality of life of patients with malignant pleural effusion and ascites, while not causing notable adverse events.
科研通智能强力驱动
Strongly Powered by AbleSci AI